A recent study has demonstrated that reducing tau levels and phosphorylation by intraocular injection of tau-specific siRNA can protect RGCs from hypertension-induced damage in a rodent model of glaucoma [33], making it a promising strategy to limit the toxic effects of tau. The gene discussed is MAPT; the disease is hypertensive disorder.